Schizophrenia
Schizophrenia can affect how a person perceives reality, thinks and feels, sometimes involving hearing voices or holding unusual beliefs.
CompletedNCT00525304
Official study titleOptimizing Chronic Illness Self-Management for Individuals With Schizophrenia
This study has finished and is no longer accepting participants.
In BaltimoreSchizophreniaBehavioural studyAges 18–64
- Countries
- United States
- Sponsor
- University of Maryland, Baltimore
CompletedNCT01942161
What is this study about?Researchers compared Aripiprazole Low (2 mg/day), Aripiprazole Mid (6 - 12 mg/day) and Aripiprazole High (24 - 30 mg/day) to find out how the approaches affected psychotic symptoms in children with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including Chubu RegionSchizophreniaMedication studyAges 13–17
- Countries
- Japan
- Sponsor
- Otsuka Pharmaceutical Co., Ltd. (Pharmaceutical company)
CompletedNCT00640510
What is this study about?Researchers compared Rapid Acting Intramuscular Olanzapine and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including FukushimaSchizophreniaMedication studyAges 20–64
- Countries
- Japan
- Sponsor
- Eli Lilly and Company
CompletedNCT00649844
Official study titleDouble Blind, Double-Dummy Multicenter, Parallel Group Comparison Of The Efficacy And The Tolerability Of Ziprasidone Vs. Clozapine In Schizophrenic Patients Who Are Refractory And/Or Intolerant To Antipsychotic Therapy
This study has finished and is no longer accepting participants.
Multiple locations, including Città di CastelloSchizophreniaMedication studyAges 18+
- Countries
- Italy
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
TerminatedNCT00645515
Official study titleZiprasidone Versus Risperidone In The Treatment Of Chronic Schizophrenia: A Six Months, Double Blind Randomized, Parallel Group Study
This study ended early.
Multiple locations, including BilbaoSchizophreniaMedication studyAges 18–70
- Countries
- Spain
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
CompletedNCT00999895
Official study titleA Non-interventional, Prospective, Open-label Study for the Evaluation of the Selection and Outcome of the Antipsychotic Treatment Switch in Outpatients With Schizophrenia - ETOS Study
This study has finished and is no longer accepting participants.
Multiple locations, including PátraiSchizophreniaObservational studyAges 18–65
- Countries
- Greece
- Sponsor
- AstraZeneca
CompletedNCT00520923
What is this study about?Researchers compared LY2140023, placebo and Olanzapine and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including BanfieldSchizophreniaMedication studyAges 18–65
- Countries
- Argentina, Austria, Croatia, + 6 others
- Sponsor
- Denovo Biopharma LLC
TerminatedNCT01125358
Official study titleA Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 in Patients With DSM-IV-TR Schizophrenia
This study ended early.
Multiple locations, including AichiSchizophreniaMedication studyAges 20–65
- Countries
- Japan, South Korea, Taiwan
- Sponsor
- Denovo Biopharma LLC
TerminatedNCT01077791
Official study titleCognitive Remediation of the Ability to Infer Intention of Others in Schizophrenic Patients - A Controlled, Randomized Trial (Phase IIb)
This study ended early.
In Le ChesnaySchizophreniaBehavioural studyAges 18–57
- Countries
- France
- Sponsor
- Assistance Publique - Hôpitaux de Paris
CompletedNCT00300846
Official study titleA Multicenter, Comparative, Randomized, Double-Blind, Placebo Controlled Study on the Effect on Weight of Adjunctive Treatment With Aripiprazole in Patients With Schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including GrazSchizophreniaMedication studyAges 18–65
- Countries
- France, United Kingdom, Switzerland, + 9 others
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)
CompletedNCT00567203
What is this study about?This study evaluated the safety and effectiveness of PF-3463275 for people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including GlendaleSchizophreniaMedication studyAges 18–55
- Countries
- United States
- Sponsor
- Pfizer
CompletedNCT02634346
What is this study about?Researchers compared ALK3831, Olanzapine and placebo to find out how the approaches affected psychotic symptoms in adults with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including Little RockSchizophreniaMedication studyAges 18–70
- Countries
- United States, Bulgaria, Serbia, + 1 other
- Sponsor
- Alkermes, Inc.